Clinical Trial Ambassador Conference
The CT-Ambassador Conference provides first hand information about recruiting clinical trials by the industry and the investigators to the CT-Ambassadors. This ensures that Clinical Trial Ambassadors are regularely updated about clinical trials.
The participants of CT-Ambassador Conferences are exclusively CT-Ambassadors and candidates, industry medical and patient relations representatives and investigators.
Next Clinical Trial Ambassador Conference 2024
22. March 2025
You are an investigator or pharmaceutical company and would like to present your recruiting clinical trials to the Clinical Trial Ambassadors please contact us.
Clinical Trial Ambassador Conference 2024
9. November 2024
The following clinical trials have been presented.
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
Sponsor: Pfizer
Purpose of this study?
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment), or until marketing authorization is obtained in the participant's country, whichever comes first.
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Sponsor: Seagen Inc.
Purpose of this study?
This clinical trial is studying nonsquamous non-small cell lung cancer (NSCLC). Participants in this study must have cancer that has spread through their body or can't be removed with surgery. Participants in this study must have been treated with no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. Participants with tumors that have certain treatable genomic alterations must have had at least 1 drug for that genomic alteration, in addition to platinum-based chemotherapy.
This clinical trial uses an experimental drug called sigvotatug vedotin, which is a type of antibody drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. This clinical trial also uses a drug called docetaxel. Docetaxel is an anticancer drug that has been approved to treat non-small cell lung cancer. It is usually given to patients who previously received another anticancer treatment. In this study, one group of participants will get sigvotatug vedotin on Days 1 and 15 during each 28-day-cycle. A second group of participants will get docetaxel on Day 1 during each 21-day cycle.
This study is being done to see if sigvotatug vedotin works better than docetaxel to treat participants with NSCLC. This study will also test what side effects happen when participants take these drugs. A side effect is anything a drug does to the body besides treating the disease.
Clinical Trial Ambassador Conference 2024
22. June 2024
The following clinical trials have been presented.
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients (REASON)
Sponsor: Janssen-Cilag Ltd.
Purpose of this study?
The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.
Clinical Trial Ambassador Conference 2024
23. March 2024
Clinical Trial Ambassador Conference 21 October 2023
The following clinical trials have been presented.
A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis (GALARISSO)
Sponsor: Galapagos NV
Purpose of this study?
The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered GLPG3667 once daily for 24 weeks in adult participants with dermatomyositis (DM).
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus (GALACELA)
Sponsor: Galapagos NV
Purpose of this study?
A Study Evaluating the Effects of GLPG3667 Administered as Oral Treatment in Adult Participants With Active Systemic Lupus Erythematosus (GALACELA)
A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease (FUZION CD)
Sponsor: Janssen
Purpose of this study?
The purpose of this study to evaluate the clinical efficacy of guselkumab in fistulizing, perianal Crohn's disease and to assess the overall safety of guselkumab.
Clinical Trial Ambassador Conference 14 March 2023
The following clinical trials have been presented.
A Study of Modakafusp Alfa Together With Daratumumab Adults With Relapsed or Refractory Multiple Myeloma (iinnovate-3)
Sponsor: Takeda
Purpose of this study?
The main aim of this study is to determine safety and tolerability of modakafusp alfa given together with daratumumab to find out the best treatment dose. Another aim of this study is to learn more about the characteristics of modakafusp alfa.
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM-7)
Sponsor: Pfizer
Purpose of this study?
The purpose of this study is to evaluate whether elranatamab monotherapy can provide clinical benefit compared to lenalidomide monotherapy (control) in participants with newly diagnosed multiple myeloma after undergoing autologous stem cell transplant. Participants in the study will either receive elranatamab as an injection under the skin at the study clinic or lenalidomide orally once daily at home. Participation in the study will be approximately five years.
MagnetisMM-5: Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma (MAGNETISMM-5)
Sponsor: Pfizer
Purpose of this study?
The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone.
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135), Daratumumab, and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant (MagnetisMM-6)Neuer Text
Sponsor: Pfizer
Purpose of this study?
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the study is to evaluate if the combination of Elranatamab, Daratumumab and Lenalidomide offers superior clinical benefit compared with the combination of Daratumumab, Lenalidomide and Dexamethasone in people with multiple myeloma.
Study to Evaluate CC-92480 in Combination With Carfilzomib and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Sponsor: Bristol-Myers Squibb
Purpose of this study?
The purpose of the study is to compare the efficacy and safety of CC-92480 with carfilzomib and dexamethasone (480Kd) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM.
Approximately 525 patients will be enrolled in the study.
A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)
Sponsor: Bristol-Myers Squibb
Purpose of this study?
The purpose of this study is to compare the efficacy and safety of CC-92480, bortezomib and dexamethasone (480Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Approximately 760 patients will be enrolled in the study.
Clinical Trial Ambassador Conference November 2022
Clinical Trial Ambassador Conference 21 May 2022
The following clinical trials have been presented.
Fecal Microbiota Transplantation in Patients with Ulcerative Colitis Incompletely Responding to Vedolizumab
Investigator: Prof. Christoph Högenauer, Medical University Graz
Purpose of this study?
Treatment response to FMT in UC in patients not or incompletely responding to vedolizumab
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 2a Study to Evaluate the Safety, Tolerability, and Early Proof of Concept of TAK-018 for
the Prevention of Postoperative Crohn’s Disease Recurrence.
Sponsor: Takeda
Purpose of this study?
To assess the safety and tolerability of TAK-018 in postoperative subjects with CD after laparoscopic ileocecal resection with primary anastomosis.
A Study on Administration Choices of Vedolizumab and Outcomes for Adults With Inflammatory Bowel Disease (IBD)
Sponsor: Takeda
Purpose of this study?
To describe real-world treatment patterns in adults with moderate to severe ulcerative colitis or Crohn's disease when treated with vedolizumab. This will include the administration choices which can either be an infusion through a vein (intravenous or IV), or an injection just under the skin (subcutaneous injection, or SC).
Treatment will be determined by the study doctor according to routine clinical practice.
YELLOWSTONE – Induction Study (RPC01-3201 and 3202) – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease
Sponsor: Bristol-Myers Squibb, Celgen
Purpose of this study?
To evaluate the safety and effectiveness of an oral investigational drug (ozanimod) which is taken once daily.
Clinical Trial Ambassador Conference 20.11.2021
The following clinical trials have been presented.
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Patients With Moderate To Severe Crohn's Disease
Sponsor: Pfizer
Purpose of this study?
The objectives of this study are to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06651600 (200 mg for 8 weeks followed by 50 mg for 4 wspectively, for 52 weeks.
A Randomized, Multi-center, Participant and Investigator-blinded, Placebo-controlled, Parallel-group Study to Assess the Efficacy Safety and Tolerability of LYS006 in Patients With Mild to Moderate Ulcerative Colitis
Sponsor: Novartis
Purpose of this study?
The purpose of the study is to assess preliminary efficacy, safety, and tolerability of LYS006 in patients with mild to moderate ulcerative colitis and to determine if LYS006 has an adequate clinical profile for further development in this indication.
Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula
Sponsor: Takeda
Purpose of this study?
The purpose of this study is to evaluate the long-term safety of a single dose of darvadstrocel in participants with Crohn's disease (CD) and complex perianal fistula by evaluation of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESIs).
A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study (LOVE-CD)
Sponsor: Takeda, Geert D'Haens, Prof
Purpose of this study?
This is an investigator-initiated open label study of VDZ therapy in 2 distinct populations of CD patients with active disease: 1. patients who have been diagnosed < 2 years ago and who only been exposed to aminosalicylates and corticosteroids and 2. patients who have been exposed to immunomodulators and/or anti-TNF agents in addition to steroids and aminosalicylates.
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)
Sponsor: Janssen
Purpose of this study?
The purpose of the study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.